{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T08:20:22Z","timestamp":1771834822423,"version":"3.50.1"},"reference-count":72,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2025.2025.0330","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T05:56:01Z","timestamp":1766469361000},"source":"Crossref","is-referenced-by-count":0,"title":["2025 Update of Cellular Immunotherapy for Plasma Cell Disorders"],"prefix":"10.4274","author":[{"given":"Ece","family":"Vural","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merak","family":"Beksa\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","unstructured":"1. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Moreau P. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial. J Clin Oncol. 2023;41:1590-1599.","journal-title":"J Clin Oncol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","unstructured":"2. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Sch\u00f6nland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385:46-58.","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","unstructured":"3. Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosi\u00f1ol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Blad\u00e9 J, Moreau P; PERSEUS Trial Investigators. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301-313.","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","unstructured":"4. Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, Poondla N, Tanzadehpanah H, Dirbaziyan A, Mahaki H, Manoochehri H, Kalhor N, Dama P. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther. 2024;31:667-686.","journal-title":"Cancer Gene Ther"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Hashim L, Faisal MS, Iqbal MA, Saeed H, Samhouri Y, Shahzad M, Khattak ZE, Anwer F. Bispecific T-cell engager antibodies in multiple myeloma- a systematic review of phase 1 clinical trials. Blood. 2021;138(Suppl 1):4775.","DOI":"10.1182\/blood-2021-153859"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1499590","DOI":"10.3389\/fimmu.2025.1499590","article-title":"CAR-T cells in the treatment of multiple myeloma: an encouraging cell therapy","volume":"16","author":"Yu","year":"2025","unstructured":"6. Yu T, Jiao JH, Wu MF. CAR-T cells in the treatment of multiple myeloma: an encouraging cell therapy. Front Immunol. 2025;16:1499590.","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","unstructured":"7. Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688-1700.","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Raje NS, Shah N, Jagannath S, Kaufman JL, Siegel DS, Munshi NC, Rosenblatt J, Lin Y, Jakubowiak A, Timm A, Yeri A, Martin N, Campbell TB, Finney O, Truppel-Hartmann A, Petrocca F, Berdeja JG, Alsina M. Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma. Blood. 2021;138(Suppl 1):548.","DOI":"10.1182\/blood-2021-146518"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","unstructured":"9. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726-1737.","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Usmani S, Patel K, Hari P, Berdeja J, Alsina M, Vij R, Raje N, Leleu X, Dhodapkar M, Reshef R, Truppel-Hartmann A, Basudhar D, Thompson E, Zheng X, Ananthakrishnan R, Greggio C, Favre-Kontula L, Sternas L, San-Miguel J. KarMMa-2 Cohort 2a: efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. Blood. 2022;140(Suppl 1):875-877.","DOI":"10.1182\/blood-2022-162469"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Usmani SZ, Berdeja JG, Truppel-Hartmann A, Fei Y, Wortman-Vayn H, Shelat S, Novick S, Shah N. KarMMa-4: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma. J Clin Oncol. 2021;39(Suppl):TPS8053 (abstract).","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8053"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2217\/fon-2023-0954","article-title":"Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma","volume":"20","author":"Rodriguez-Otero","year":"2024","unstructured":"12. Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma. Future Oncol. 2024;20:1221-1235.","journal-title":"Future Oncol"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Raje NS, Berdeja JG, Rodriguez-Otero P, Green DJ, Jagannath S, Lonial S, Gipson A, Caia A, Martin N, Yang Z, Pittari G, Mateos MV. KarMMa-7, a phase 1\/2, dose-finding and dose-expansion study of combination therapies with idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy for relapsed\/refractory multiple myeloma (RRMM). Blood. 2021;138(Suppl 1):4830.","DOI":"10.1182\/blood-2021-147412"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Lin Y, Martin TG, Usmani SZ, Berdeja JG, Jakubowiak AJ, Agha ME, Cohen AD, Deol A, Htut M, Lesokhin AM, Munshi NC, O'Donnell E, Jackson CC, Yeh T, Banerjee A, Zudaire E, Madduri D, delCorral C, L. Bubuteishvili-Pacaud L, Jagannath S. CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2023;41(Suppl):8009 (abstract).","DOI":"10.1200\/JCO.2023.41.16_suppl.8009"},{"key":"ref14","unstructured":"15. Johnson & Johnson. U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI\u00ae (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma. New Brunswick, Johnson & Johnson, 2024. Available at https:\/\/www.jnj.com\/media-center\/press-releases\/u-s-fda-oncologic-drugs-advisory-committee-recommends-carvykti-ciltacabtagene-autoleucel-for-the-earlier-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Hillengass J, Cohen AD, Delforge M, Einsele H, Goldschmidt H, Weisel K, Raab MS, Scheid C, Schecter JM, de Braganca KC, Varsos H, Yeh T, Mistry P, Roccia T, Corsale C, Akram M, Pacaud L, Nesheiwat T, Agha M, Cohen YC. MM-183 CARTITUDE-2 Cohort A: updated clinical data and biological correlative analyses of ciltacabtagene autoleucel (cilta-cel) in lenalidomide-refractory patients with progressive multiple myeloma (MM) after 1-3 prior lines of therapy (LOT). Clin Lymphoma Myeloma Leuk. 2022;22(Suppl 2):S411.","DOI":"10.1016\/S2152-2650(22)01600-7"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Dhakal B, Yong K, Harrison SJ, Mateos MV, Moreau P, van de Donk NWCJ, Sidana S, Popat R, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Li K, Zudaire E, Chen Y, Gilbert J, Bubuteishvili-Pacaud L, Patel N, San-Miguel J, Einsele H. First phase 3 results from CARTITUDE-4: cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. J Clin Oncol. 2023;41(Suppl):LBA106.","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA106"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","unstructured":"18. Xu J, Wang BY, Yu SH, Chen SJ, Yang SS, Liu R, Chen LJ, Hou J, Chen Z, Zhao WH, He AL, Mi JQ, Chen SJ. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol. 2024;17:23.","journal-title":"J Hematol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Mikkilineni L, Manasanch EE, Natrakul D, Weissler K, Brudno JN, Mann J, Goff SL, Yang JC, Lam N, Maric I, Wang HW, Yuan CM, Stroncek DF, Highfill S, Ganadan M, Patel R, Rosenberg SA, Kochenderfer JN. T cells expressing a fully-human anti-BCMA chimeric antigen receptor with a heavy-chain-only antigen-recognition domain exhibit rapid and durable activity against multiple myeloma. Blood. 2022;140(Suppl 1):7433-7434.","DOI":"10.1182\/blood-2022-159156"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Fu C, Chen W, Cai Z, Yan L, Wang H, Shang J, Wu Y, Yan S, Gao W, Shi X, Han X, Tang F, Zheng G, Wen Y, Meng X, Zheng W, Wang H, Li Z. Three-year follow-up on efficacy and safety results from phase 1 Lummicar Study 1 of zevorcabtagene autoleucel in Chinese patients with relapsed or refractory multiple myeloma. Blood. 2023;142(Suppl 1):4845.","DOI":"10.1182\/blood-2023-184373"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Mailankody S, Matous JV, Liedtke M, Sidana S, Oluwole OO, Mohan M, Cruz JC, Nath R, Anwer F, Rossi A, Htut M, Malik SA, Ghatta S, Dillon M, Ying W, Navale L, Karski EE, Balakumaran A, Kumar SK. Universal updated phase 1 data highlights role of allogeneic anti-BCMA ALLO-715 therapy for relapsed\/refractory multiple myeloma. Blood. 2022;140(Suppl 1):4620-4622.","DOI":"10.1182\/blood-2022-158231"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.1038\/s41467-022-35127-2","article-title":"Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma","volume":"13","author":"Cichocki","year":"2022","unstructured":"22. Cichocki F, Bjordahl R, Goodridge JP, Mahmood S, Gaidarova S, Abujarour R, Davis ZB, Merino A, Tuininga K, Wang H, Kumar A, Groff B, Witty A, Bonello G, Huffman J, Dailey T, Lee TT, Malmberg KJ, Walcheck B, H\u00f6pken U, Rehm A, Valamehr B, Miller JS. Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma. Nat Commun. 2022;13:7341.","journal-title":"Nat Commun"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","unstructured":"23. Swan D, Madduri D, Hocking J. CAR-T cell therapy in multiple myeloma: current status and future challenges. Blood Cancer J. 2024;14:206.","journal-title":"Blood Cancer J"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Mailankody S, Ghosh A, Staehr M, Purdon TJ, Roshal M, Halton E, Diamonte C, Pineda J, Anant P, Bernal Y, Wills A, Korde N, Lendvai N, Lesokhin AM, Hassoun H, Hultcrantz M, Landau HJ, Shah GL, Scordo M, Chung DJ, Lahoud OB, Khattar P, Fernandez de Larrea C, Gao Q, Jungbluth A, Park JH, Curran KJ, Sauter CS, Palomba ML, Senechal B, Wang X, Dogan A, Giralt S, Riviere I, Landgren O, Brentjens RJ, Smith EL. Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: final results of a phase I clinical trial. Blood. 2018;132(Suppl 1):959.","DOI":"10.1182\/blood-2018-99-119717"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Zhang M, Wei G, Zhou L, Zhou J, Chen S, Zhang W, Wang D, Luo X, Cui J, Huang S, Fu S, Zhou X, Tang Y, Ding X, Kuang J, He XP, Hu Y, Huang H. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023;10:e107-e116.","DOI":"10.1016\/S2352-3026(22)00372-6"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Zhou D, Sun Q, Xia J, Gu W, Qian J, Zhuang W, Yan Z, Cheng H, Chen W, Zhu F, Qi K, Li D, Sang W, Zhu L, Ma S, Li H, Zhang H, Qiu T, Yan D, Zhang Y, Peng S, Chang AH, Xu K, Li Z. Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. Lancet Haematol. 2024;11:e751-e760.","DOI":"10.1016\/S2352-3026(24)00176-5"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Popat R, Larson SM, Varshavsky Yanovsky A, Bal S, Raab MS, Grazioli K, Basudhar D, Hu H, Meng Y, Eldjerou L, Harrison SJ, Rodr\u00edguez-Otero P. QUINTESSENTIAL-2: a phase 3 study comparing efficacy and safety of arlocabtagene autoleucel (arlo-cel) versus standard regimens in adult patients with relapsed or refractory multiple myeloma (RRMM) refractory to lenalidomide. J Clin Oncol. 2025;43(Suppl):TPS7564 (abstract).","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7564"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","article-title":"Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma","volume":"14","author":"Jiang","year":"2023","unstructured":"28. Jiang D, Huang H, Qin H, Tang K, Shi X, Zhu T, Gao Y, Zhang Y, Tian X, Fu J, Qu W, Cai W, Xu Y, Wu D, Chu J. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma. Nat Commun. 2023;14:3642.","journal-title":"Nat Commun"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/leu.2016.211","article-title":"Differentiation stage of myeloma plasma cells: biological and clinical significance","volume":"31","author":"Paiva","year":"2017","unstructured":"29. Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martinez-Lopez J, Cordon L, Alignani D, Delgado JA, van Zelm MC, Van Dongen JJ, Pascual M, Agirre X, Prosper F, Mart\u00edn-Subero JI, Vidriales MB, Gutierrez NC, Hernandez MT, Oriol A, Echeveste MA, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Morgan GJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, San-Miguel JF. Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia. 2017;31:382-392.","journal-title":"Leukemia"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Du J, Fu W, Jiang H, Dong B, Gao LI, Liu LI, Ge J, He A, LI L, Lu J, Chen X, Liu J, Zhang Q, He J, Weng L, Zhang H, Shen L, Cao W, LI W. P869: updated results of a phase I, open-label study of BCMA\/CD19 dual-targeting FasTCAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM). Hemasphere. 2023;7(Suppl):e84060bf.","DOI":"10.1097\/01.HS9.0000970380.84060.bf"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","unstructured":"31. Li C, Xu J, Luo W, Liao D, Xie W, Wei Q, Zhang Y, Wang X, Wu Z, Kang Y, Zheng J, Xiong W, Deng J, Hu Y, Mei H. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia. 2024;38:149-159.","journal-title":"Leukemia"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Lee L, Lim WC, Galas-Filipowicz D, Fung K, Taylor J, Patel D, Akbar Z, Alvarez Mediavilla E, Wawrzyniecka P, Shome D, Reijmers RM, Gregg T, Wood L, Day W, Cerec V, Ferrari M, Thomas S, Cordoba S, Onuoha S, Khokhar N, Peddareddigari V, Al-Hajj M, Cavet J, Zweegman S, Rodriguez-Justo M, Youg K, Pule M, Popat R. Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy. J Immunother Cancer. 2023;11:e006699.","DOI":"10.1136\/jitc-2023-006699"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","unstructured":"33. Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D, Guo T, Kou H, Liu L, Tang L, Yin P, Wang Z, Ai L, Ke S, Xia Y, Deng J, Chen L, Cai L, Sun C, Xia L, Hua G, Hu Y. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021;14:161.","journal-title":"J Hematol Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1158\/1078-0432.CCR-23-0132","article-title":"Specific targeting of multiple myeloma by dual split-signaling chimeric antigen receptor T cells directed against CD38 and CD138","volume":"29","author":"van der Schans","year":"2023","unstructured":"34. van der Schans JJ, Wang Z, van Arkel J, van Schaik T, Katsarou A, Ruiter R, Baardemans T, Yuan H, de Bruijn J, Zweegman S, van de Donk NWCJ, Groen RWJ, Themeli M, Mutis T. Specific targeting of multiple myeloma by dual split-signaling chimeric antigen receptor T cells directed against CD38 and CD138. Clin Cancer Res. 2023;29:4219-4229.","journal-title":"Clin Cancer Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-0716-2441-8_3","article-title":"Generation of CAR-T cells with Sleeping Beauty transposon gene transfer","volume":"2521","author":"Prommersberger","year":"2022","unstructured":"35. Prommersberger S, Monjezi R, Botezatu L, Miskey C, Amberger M, Mestermann K, Hudecek M, Ivics Z. Generation of CAR-T cells with Sleeping Beauty transposon gene transfer. Methods Mol Biol. 2022;2521:41-66.","journal-title":"Methods Mol Biol"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. Oliver-Caldes A, Gonzalez-Calle V, Caba\u00f1as V, Lopez-Mu\u00f1oz N, Rodriguez Otero P, Reguera JL, Espa\u00f1ol-Rego M, Inoges S, Zabaleta A, Lopez Corral L, Martin-Antonio B, Perez-Amill L, Paiva B, Rosi\u00f1ol L, L\u00f3pez-D\u00edaz De Cerio A, Navarro S, Cid J, Tovar N, Saez-Pe\u00f1ataro J, Lopez Parra M, Olesti E, Guill\u00e9n E, Varea S, Delgado J, Sanchez Pina JM, Battram A, Gonzalez Perez MS, Sanchez Salinas A, Ortiz-Maldonado V, Prosper F, Juan M, Martinez Lopez J, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fern\u00e1ndez de Larrea C. ARI0002h (cesnicabtagene autoleucel), an academic point-of-care B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell strategy: activity and safety after fractionated initial therapy and booster dose in 60 patients with relapsed\/refractory multiple myeloma. Blood. 2023;142(Suppl 1):1026.","DOI":"10.1182\/blood-2023-180828"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1182\/bloodadvances.2024012967","article-title":"Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed\/refractory multiple myeloma","volume":"8","author":"Kfir-Erenfeld","year":"2024","unstructured":"37. Kfir-Erenfeld S, Asherie N, Lebel E, Vainstein V, Assayag M, Dubnikov Sharon T, Grisariu S, Avni B, Elias S, Alexander-Shani R, Bessig N, Shehadeh A, Ishtay A, Zelmanovich V, Zimran E, Pick M, Roziner I, Kenett RS, Cohen Y, Avivi I, Cohen CJ, Gatt ME, Stepensky P. Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed\/refractory multiple myeloma. Blood Adv. 2024;8:4077-4088.","journal-title":"Blood Adv"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. Kleinsorge-Block S, Giraudo M, Idipilly N, Caley D, Reese-Koc J, Arunachalam A, Chaekal O, Sheets M, Purgert R, Melenhorst J, Farooq U, Caimi P, Deng C, Wald D, van Besien K, Gallogly M. Development and clinical validation of a less than 1 day CAR-T manufacturing process. Cytotherapy. 2025;27:S15.","DOI":"10.1016\/j.jcyt.2025.03.016"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","unstructured":"39. Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Massaro M, Petrocca F, Yeri A, Finney O, Caia A, Yang Z, Martin N, Campbell TB, Rytlewski J, Fuller J, Hege K, Munshi NC, Kochenderfer JN. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29:2286-2294.","journal-title":"Nat Med"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. Hansen DK, Patel KK, Peres LC, Kocoglu MH, Shune L, Simmons G, Ferreri CJ, Atrash S, Parrondo RD, Chhabra S, Costello P, Midha S, Alsina M, Voorhees PM, Htut M, Sborov DW, Khouri J, Janakiram M, Lin Y, Sidana S. Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (cilta-cel) for relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(Suppl):8012 (abstract).","DOI":"10.1200\/JCO.2023.41.16_suppl.8012"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41. Bangolo AI, Gill SK, Amoozgar B, Dey S, Slotky R, Siegel DS, Parmar H, Biran N, Vesole DH, Phull P. Real world outcomes of multiple myeloma patients who underwent apheresis for planned chimeric antigen receptor (CAR) T cell therapy: a single center experience. Blood. 2024;144(Suppl 1):7097.","DOI":"10.1182\/blood-2024-211895"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42. Merz M, Albici AM, von Tresckow B, Rathje K, Fenk R, Holderried T, M\u00fcller F, Tovar N, Oliver-C\u00e1ldes A, Vucinic V, Kharboutli S, B\u00e4rmann BN, Ayuk F, Platzbecker U, St\u00f6lzel F, Schub N, Schmitz F, Fandrei D, Born P, Khandanpour C, Hanoun C, H\u00f6rster K, Teichert M, Jeker B, Hoffmann M, Kr\u00f6ger N, de Larrea CF, Pabst T, Gagelmann N. Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: an international multicenter study. Hemasphere. 2025;9:e70070.","DOI":"10.1002\/hem3.70070"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.3390\/curroncol31070292","article-title":"Review of CAR T-cell therapy in multiple myeloma: a Canadian perspective","volume":"31","author":"SC","year":"2024","unstructured":"43. Shih SC, Bhella S. Review of CAR T-cell therapy in multiple myeloma: a Canadian perspective. Curr Oncol. 2024;31:3949-3967.","journal-title":"Curr Oncol"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44. Sidana S, Ahmed N, Akhtar OS, Heim M, Brazauskas R, Hansen DK, Ferreri C, Freeman CLL, Afrough A, Anderson LD, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison M, Kitali A, Mirza S, Patel J, Patwardhan P, Usmani SZ, Patel KK, Ganguly S, Pasquini M. Real world outcomes with idecabtagene vicleucel (ide-cel) CAR-T cell therapy for relapsed\/refractory multiple myeloma. Blood. 2023;142(Suppl 1):1027.","DOI":"10.1182\/blood-2023-181762"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","unstructured":"45. Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium. J Clin Oncol. 2023;41:2087-2097.","journal-title":"J Clin Oncol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","unstructured":"46. Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59.","journal-title":"Blood Cancer J"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41408-022-00719-0","article-title":"Smoldering multiple myeloma current treatment algorithms","volume":"12","author":"Rajkumar","year":"2022","unstructured":"47. Rajkumar SV, Kumar S, Lonial S, Mateos MV. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 2022;12:129.","journal-title":"Blood Cancer J"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48. Nadeem O, Nikiforow S, DeBraganca K, Bosch-Vilaseca A, O'Donnell EK, Sperling AS, Liu Y, Arters F, Marto M, O'Donnell C, Kineavy B, Holmes S, Wei H, Durlacher E, Grimm E, Goguen A, Montes de Oca R, Trippa L, Smith EL, Anderson KC, Munshi NC, Wildgust M, Ritz J, Tendler C, Ghobrial I. Early safety and efficacy of CAR-T cell therapy in precursor myeloma: results of the CAR-PRISM study using ciltacabtagene autoleucel in high-risk smoldering myeloma. Blood. 2024;144(Suppl 1)1027.","DOI":"10.1182\/blood-2024-202676"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41408-021-00486-4","article-title":"Comprehensive review of AL amyloidosis: some practical recommendations","volume":"11","author":"Al Hamed","year":"2021","unstructured":"49. Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M. Comprehensive review of AL amyloidosis: some practical recommendations. Blood Cancer J. 2021;11:97.","journal-title":"Blood Cancer J"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4274\/balkanmedj.galenos.2025.2025-4-25","article-title":"Current anti-myeloma chimeric antigen receptor-T cells: novel targets and methods","volume":"42","author":"Vural","year":"2025","unstructured":"50. Vural E, Beksa\u00e7 M. Current anti-myeloma chimeric antigen receptor-T cells: novel targets and methods. Balkan Med J. 2025;42:301-310.","journal-title":"Balkan Med J"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1111\/bjh.19896","article-title":"Are we there yet? CAR-T therapy in multiple myeloma","volume":"205","author":"Mirvis","year":"2024","unstructured":"51. Mirvis E, Benjamin R. Are we there yet? CAR-T therapy in multiple myeloma. Br J Haematol. 2024;205:2175-2189.","journal-title":"Br J Haematol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma","volume":"42","author":"Gagelmann","year":"2024","unstructured":"52. Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Cald\u00e9s A, St\u00f6lzel F, Rathje K, Fischer L, Born P, Sch\u00e4fer L, Albici AM, Schub N, Kfir-Erenfeld S, Assayag M, Asherie N, Wulf GG, Kharboutli S, M\u00fcller F, Shune L, Davis JA, Anwer F, Vucinic V, Platzbecker U, Ayuk F, Kr\u00f6ger N, Khouri J, Gurnari C, McGuirk J, Stepensky P, Abdallah AO, Fern\u00e1ndez de Larrea C. Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:1665-1675.","journal-title":"J Clin Oncol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","unstructured":"53. Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705-716.","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","unstructured":"54. Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN 3rd, Coffey DG, Tuazon SA, Wood B, Gooley T, Wu VQ, Voutsinas J, Song X, Shadman M, Gauthier J, Chapuis AG, Milano F, Maloney DG, Riddell SR, Green DJ. \u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023;24:811-822.","journal-title":"Lancet Oncol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1279740","DOI":"10.3389\/fnmol.2023.1279740","article-title":"Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease","volume":"16","author":"Nordvall","year":"2023","unstructured":"55. Nordvall G, Lundkvist J, Sandin J. Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease. Front Mol Neurosci. 2023;16:1279740.","journal-title":"Front Mol Neurosci"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","unstructured":"56. Garfall AL, Dancy EK, Cohen AD, Hwang WT, Fraietta JA, Davis MM, Levine BL, Siegel DL, Stadtmauer EA, Vogl DT, Waxman A, Rapoport AP, Milone MC, June CH, Melenhorst JJ. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3:2812-2815.","journal-title":"Blood Adv"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2643-3230.BCD-24-0118","article-title":"Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma","volume":"6","author":"Fandrei","year":"2025","unstructured":"57. Fandrei D, Seiffert S, Rade M, Rieprecht S, Gagelmann N, Born P, Wiemers T, Weidner H, Kreuz M, Schassberger T, Ko\u00dfmann J, Mangold M, F\u00fcrst D, Fischer L, Baber R, Heyn S, Wang SY, Bach E, Hoffmann S, Metzeler KH, Herling M, Jentzsch M, Franke GN, K\u00f6hl U, Friedrich M, Boldt A, Reiche K, Platzbecker U, Vucinic V, Merz M. Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma. Blood Cancer Discov. 2025;6:38-54.","journal-title":"Blood Cancer Discov"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-18-0551","article-title":"BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy","volume":"7","author":"Smith","year":"2019","unstructured":"58. Smith EL, Mailankody S, Staehr M, Wang X, Senechal B, Purdon TJ, Daniyan AF, Geyer MB, Goldberg AD, Mead E, Santomasso BD, Landa J, Rimner A, Riviere I, Landgren O, Brentjens RJ. BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy. Cancer Immunol Res. 2019;7:1047-1053.","journal-title":"Cancer Immunol Res"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s10555-024-10219-1","article-title":"CAR T-cell therapy to treat multiple myeloma: current state and future directions","volume":"44","author":"Reddy","year":"2024","unstructured":"59. Reddy ST, Hosoya H, Mikkilineni L. CAR T-cell therapy to treat multiple myeloma: current state and future directions. Cancer Metastasis Rev. 2024;44:14.","journal-title":"Cancer Metastasis Rev"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","article-title":"NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors","volume":"7","author":"Parihar","year":"2019","unstructured":"60. Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, Gottschalk SM, Rooney CM. NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol Res. 2019;7:363-375.","journal-title":"Cancer Immunol Res"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","unstructured":"61. Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133:697-709.","journal-title":"Blood"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","unstructured":"62. Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581-590.","journal-title":"Nat Med"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41587-024-02339-4","article-title":"A CAR enhancer increases the activity and persistence of CAR T cells","volume":"43","author":"Rakhshandehroo","year":"2025","unstructured":"63. Rakhshandehroo T, Mantri SR, Moravej H, Louis BBV, Salehi Farid A, Munaretto L, Regan K, Khan RMM, Wolff A, Farkash Z, Cong M, Kuhnast A, Nili A, Lee UJ, Allen HH, Berland L, Simkova E, Uslu SC, Tavakolpour S, Rowley JE, Codet E, Shahbazian H, Baral J, Pyrdol J, Jacobson CA, Nadeem O, Nia HT, Wucherpfennig KW, Rashidian M. A CAR enhancer increases the activity and persistence of CAR T cells. Nat Biotechnol. 2025;43:948-959.","journal-title":"Nat Biotechnol"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"64. Du J, Fu W, Lu J, Qiang W, He H, Liu J, Yang Y, Feng Z, Jin L, Fan X, Liu J, Zhang Q, Shen L, Weng L, Cao W. Phase I open-label single-arm study of BCMA\/CD19 dual-targeting FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma. Blood. 2022;140(Suppl 1):889-890.","DOI":"10.1182\/blood-2022-162295"},{"key":"ref64","unstructured":"65. Harding D, Bartlett L, Gudgeon N, Fisher J, Kashyap T, Walker C, Cragg M, Roghanian A, Khakoo S, Dimeloe S, Blunt M. Selinexor potentiates antibody-dependent cellular-cytotoxicity (ADCC) and CAR-NK cell activation against multiple myeloma cells via downregulation of HLA-E. EHA Congress. 2025:PF689 (abstract)."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","unstructured":"66. Xu J, Liu L, Parone P, Xie W, Sun C, Chen Z, Zhang J, Li C, Hu Y, Mei H. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet. 2025;406:228-231.","journal-title":"Lancet"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"67. Harrison S, Ho PJ, Lim SL, Talam S, Pahl H, Dingar D, Currence S, Quigley T, Spencer A. Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010. Blood.2025;146 (Suppl 2) LBA-1.","DOI":"10.1182\/blood-2025-LBA-1"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1126\/science.ady7928","article-title":"Engineering immunotherapy from within","volume":"388","author":"Peche","year":"2025","unstructured":"68. Peche V, Gottschalk S. Engineering immunotherapy from within. Science. 2025;388:1273-1274.","journal-title":"Science"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","unstructured":"69. Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, Wang A, Li JJ, Soldevila F, Chu DSH, Nguyen DP, Yong QC, Ross B, Nguyen M, Vestal J, Roberts S, Galvan D, Vega JB, Jhung D, Butcher M, Nguyen J, Zhang S, Fernandez C, Chen J, Herrera C, Kuo Y, Pica EM, Mondal G, Mammen AL, Scholler J, Tanis SP, Sievers SA, Frantz AM, Adams GB, Shawver L, Farzaneh-Far R, Rosenzweig M, Karmali PP, Bot AI, June CH, Aghajanian H. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388:1311-1317.","journal-title":"Science"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"12317","DOI":"10.3390\/ijms241512317","article-title":"CRISPR\/Cas9: a powerful strategy to improve CAR-T cell persistence","volume":"24","author":"Wei","year":"2023","unstructured":"70. Wei W, Chen ZN, Wang K. CRISPR\/Cas9: a powerful strategy to improve CAR-T cell persistence. Int J Mol Sci. 2023;24:12317.","journal-title":"Int J Mol Sci"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","unstructured":"71. Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM. Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43:2766-2771.","journal-title":"J Clin Oncol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","unstructured":"72. Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon S, Abrahamsen IW, Baz R, Broijl A, Chen C, Jagannath S, Raje N, Scheid C, Delforge M, Benjamin R, Pabst T, Iida S, Berdeja J, Giralt S, Truppel-Hartmann A, Chen Y, Zhong X, Wu F, Piasecki J, Eliason L, Dhanda D, Felten J, Caia A, Cook M, Popa McKiver M, Rodr\u00edguez-Otero P. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood. 2024;144:2389-2401.","journal-title":"Blood"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:56:03Z","timestamp":1771833363000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-24356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":72,"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2025.2025.0330","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"value":"1300-7777","type":"print"},{"value":"1308-5263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]}}}